New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 5, 2014
18:44 EDTTWX, SCTY, FSLR, NYMT, DRYS, FOXA, Z, CHUY, JAZZ, ZAGG, CYTX, XXIA, PBPB, ATVI, ZGNXOn The Fly: After Hours Movers
UP AFTER EARNINGS: Zogenix (ZGNX), up 8.21%... Zagg (ZAGG), up 8.9%... DryShips (DRYS), up 7%... Activision Blizzard (ATVI), up 3.1%... Jazz Pharmaceuticals (JAZZ), up 3%... New York Mortgage Trust (NYMT), up 1.4%... Potbelly (PBPB), up 1% after reporting second quarter results and announcing a $35M share repurchase program. DOWN AFTER EARNINGS: Chuy's Holdings (CHUY), down 6% after reporting second quarter results below analyst estimates and lowering fiscal 2014 guidance... First Solar (FSLR), down 4.1%... Ixia (XXIA), down 1.4% after reporting preliminary first quarter EPS below analyst estimates... Zillow (Z), down marginally after reporting quarterly results. ALSO LOWER: SolarCity (SCTY), down 1.4% after First Solar reported second quarter results... Cytori Therapeutics (CYTX), down 28.6% after announcing that it has placed enrollment in the ATHENA and ATHENA II trials on clinical hold. NOTABLE: Twenty-First Century Fox (FOXA), up 7.8% after announcing that it has withdrawn its proposal to acquire Time Warner (TWX) and announcing a $6B share repurchase program... Time Warner is trading down 9.8%.
News For ZGNX;ZAGG;DRYS;ATVI;JAZZ;NYMT;PBPB;CHUY;FSLR;XXIA;Z;SCTY;CYTX;FOXA;TWX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 >>
January 29, 2016
07:48 EDTSCTYSolarCity to benefit from new California rule, says Stifel
Subscribe for More Information
06:55 EDTJAZZ2016 could be pivotal year for Jazz, says Deutsche Bank
Deutsche Bank analyst Gregg Gilbert says 2016 could be a pivotal year for Jazz Pharmaceuticals. The analyst sees several potential catalysts for the shares, including potentially greater certainty on Xyrem duration via a patent settlement or a win in court, FDA approval of defibrotide and acquisitions supported by the company's under-leveraged balance sheet. Gilbert keeps a Buy rating on Jazz with a $167 price target.
06:23 EDTCHUYChuy's downgraded to Market Perform from Outperform at Raymond James
Raymond James downgraded Chuy's to Market Perform to reflect fair valuation, limited upside to Q4 and 2016 estimates, and elevated exposure to Texas.
06:14 EDTFOXASky names James Murdoch chairman, WSJ reports
Subscribe for More Information
January 28, 2016
18:30 EDTSCTYSolarCity issues statement on California net metering decision
Subscribe for More Information
16:40 EDTSCTYOn The Fly: Top stock stories for Thursday
The Dow began the session with triple digit gains thanks in part to solid earnings reports from some of America's bellwether corporations and oil prices, which approached $34 a barrel. The market was unable to hold its opening gains and eventually crossed into negative territory. Before the losses became too big the averages reversed and moved back across the flat line. With oil holding onto its gains and closing above $33 a barrel, the averages closed in positive territory ahead of the next barrage of earnings reports. ECONOMIC EVENTS: In the U.S., initial jobless claims fell to 278,000 last week, versus the expected 281,000 first-time claims. Durable goods orders dropped 5.1% in December, versus expectations for a decrease of 0.7%. The core reading, which removes transportation items, was down 1.2%, versus expectations for a decline of 0.1%. The National Association of Realtors' pending home sales index for December rose 0.1%, versus expectations for it to be up 0.9%. COMPANY NEWS: Shares of Facebook (FB) surged 15.5% to $109.11 after the social media giant's fourth quarter earnings and revenue beat expectations. A number of Wall Street analysts increased their price targets for the stock following the report, including Piper Jaffray's Gene Munster, who hiked his target to a "Street-high" $170 per share. Facebook management made only one mention of macro concerns for the business in 2016, significantly different than Apple's (AAPL) earnings call on Tuesday night, Munster pointed out... Caterpillar (CAT) reported better than expected quarterly earnings, excluding certain items, but its revenue came in below the consensus forecast and the heavy equipment maker warned that it does not anticipate an improvement in the world economy or commodity prices in 2016. The stock, which had declined almost 20% in the last three months prior to this morning's report, rebounded 4.7% to $61.08 after the company jumped over the lowered bar that had been set by bearish analysts... Under Armour (UA), which had similarly been the focus of concern recently for some bearish analysts, posted better than expected results on the top and bottom line and backed its fiscal year revenue forecast, proving its doubters wrong and sending its share rocketing up 22.5% to $84.00. MAJOR MOVERS: Among the notable gainers were Intrexon (XON), Inovio (INO) and Cerus (CERS), which gained a respective 10%, 7.6% and 1.4% as the ongoing Zika virus scare brought attention to the companies' efforts fighting the illness. Also higher were SolarCity (SCTY), Sunrun (RUN) and Vivint Solar (VSLR), with the solar stocks jumping 8.5%, 20.5% and 3.6%, respectively, after the California Public Utilities Commission approved new net-metering rules. Meanwhile, Eagle Pharmaceuticals (EGRX) rose 12.2% to $74.44 after announcing commercial availability of its Bendeka injection in partnership with Teva (TEVA). Among the noteworthy losers was Yahoo (YHOO), which lost 3.2% to $28.75 despite a pre-market spike after SpringOwl Asset Management urged the company to seek an investment from a strategic partner. The news was also followed by reports that CEO Marissa Mayer has started restructuring efforts with an "invest/maintain/kill" list, as well as news that Verizon (VZ) denied a report that it had bid for the company's core Internet business. Also lower were OSI Systems (OSIS), Qualcomm (QCOM) and eBay (EBAY), which fell a respective 31.8%, 8.3% and 12.5% following their quarterly earnings reports. INDEXES: The Dow rose 125.18, or 0.79%, to 16,069.64, the Nasdaq gained 38.51, or 0.86%, to 4,506.68, and the S&P 500 advanced 10.41, or 0.55%, to 1,893.36.
14:11 EDTSCTYCalifornia PUC approves new net-metering rules
The California Public Utilities Commission voted 3-2 in favor of the proposed Net Energy Metering Successor Tariff.
13:17 EDTSCTYSolarCity views MLPs better than REITs, Environmental Finance reports
Subscribe for More Information
08:36 EDTSCTYAttractive risk/reward developing in SolarCity, says Roth Capital
Roth Capital says that an attractive risk/reward ratio is developing in SolarCity, whose stock has dropped about 40% this year. However, the firm says that the company "will not be out of the woods" until California finalizes its net metering rules. The firm thinks the final net metering rules will be positive for SolarCity, but it's unsure about when the rules will be finalized, although it thinks they could be finalized later today. It keeps a $65 price target and Buy rating on SolarCity.
January 26, 2016
19:23 EDTFOXANetflix bid $20M for 'Birth of a Nation,' Bloomberg says
Subscribe for More Information
10:24 EDTSCTYNevada may let rooftop solar customers sell back power, Politico reports
Subscribe for More Information
10:00 EDTFSLROn The Fly: Analyst Initiation Summary
Today's noteworthy initiations include: Criteo (CRTO) initiated with an Equal Weight at Morgan Stanley... Devon Energy (DVN) initiated with a Buy at Citi... Fair Isaac (FICO) initiated with an Outperform at William Blair... First Solar (FSLR) initiated with a Buy at Roth Capital... Ideal Power (IPWR) initiated with a Buy at Rodman & Renshaw... Juniper Pharmaceuticals (JNP) initiated with an Outperform at Northland... MeetMe (MEET) initiated with a Buy at Topeka... MoneyGram (MGI) initiated with a Buy at Feltl... Petroleum Geo-Services (PGSVY) initiated with a Buy at HSBC... Rubicon Project (RUBI) initiated with an Equal Weight at Morgan Stanley... Smart & Final Stores (SFS) initiated with a Buy at BB&T... Tuesday Morning (TUES) initiated with a Neutral at B. Riley.
08:26 EDTFOXA, TWXTwitter in play after executive departures, says Cantor
Cantor Fitzgerald analyst Youssef Squali believes yesterday's news of several senior executives leaving Twitter (TWTR) puts the company in play and could encourage potential bidders to step forward. Twitter's current valuation and sizeable user base makes it a strategic asset for a number of potential buyers, Squali told investors last night in a research note. Potential suitors on the technology side include Alphabet (GOOG, GOOGL), Facebook (FB) and Microsoft (MSFT), the analyst contends. On the media side, Squali thinks 21st Century Fox (FOXA), Disney (DIS), Comcast (CMCSA) or Time Warner (TWX) could express interest in Twitter. No concentration of share ownership and no super-voting structure increase the odds of a buyout, Squali argues. The analyst, however, adds that the executive departures are not good news for a company in the midst of a turnaround. He maintains a Buy rating on the microblogging operator with a $45 price target. Twitter closed yesterday down 82c, or 5%, to $17.02..
08:13 EDTFSLRFirst Solar initiated with a Buy at Roth Capital
Subscribe for More Information
January 25, 2016
18:45 EDTSCTYNV Energy to propose 'grandfathering' rule in Nevada solar scuffle
Subscribe for More Information
07:47 EDTZZillow price target lowered to $32 from $38 at Canaccord
Subscribe for More Information
07:02 EDTCYTXCytori Therapeutics says Phase 3 STAR trial treats 20th patient
Cytori Therapeutics announced that its U.S. FDA approved Phase 3 STAR trial has enrolled and treated its 20th patient -- 25% of target enrollment. In addition, as per the trial protocol, an independent data monitoring committee has reviewed safety data from the initial 10 patients and recommended that the study continue as planned. The 20 procedures, including the fat harvest from small volume liposuction and the finger injections have all been completed successfully and well tolerated. STAR is a randomized, placebo-controlled, double-blind, parallel group phase III FDA approved pivotal study investigating the efficacy and safety of Cytori Cell Therapy (ECCS-50) injected subcutaneously into the fingers of patients with impaired hand function from scleroderma. A total of 80 patients will be randomized with 40 receiving Cytori Cell Therapy and 40 receiving placebo. The double-blind period extends to 48 weeks. After all patients have completed 48 weeks follow-up, the placebo patients will be offered active treatment should they desire treatment and continue to qualify. The trial began enrollment in August 2015 with enrollment expected to be completed by mid-2016. The STAR trial follows the twelve patient SCLERADEC-I pilot trial in which one year post-treatment results were published in the August 2015 edition of the journal Rheumatology. The data indicated that a single administration of ECCS-50 was safe and that treated patients exhibited significant improvements in hand symptoms, function and Raynaud's Phenomena through one-year post-treatment.
05:45 EDTSCTYSolarCity implied volatility of 116 at upper end of index mean range
Subscribe for More Information
January 24, 2016
18:28 EDTTWXAT&T potentially circling Time Warner, New York Post says
Subscribe for More Information
17:55 EDTFOXA'The Revenant' tops box office as 'Ride Along 2' sags
"The Revenant" clawed past "Ride Along 2" as this weekend's snow storm left several box office newcomers grasping for ticket sales. WEEKEND LEADER: Fox's (FOX, FOXA) "The Revenant" grossed $16M domestically for the weekend of January 24. The Leonardo DiCaprio-led survival Western was expected to take $19M-$21.6M, though results may have been dampened by the East Coast winter storm. BOX OFFICE RUNNERS-UP: Disney's (DIS) "Star Wars: The Force Awakens" earned $14.3M and now stands at $1.94B globally. Comcast (CMCSA, CMCSK) subsidiary Universal's "Ride Along 2" dipped to $13M against expectations for $18M-$18.7M, with critics and audiences generally lukewarm on the film despite its $34M open last weekend. Rounding out the weekend's top five were Lionsgate's (LGF) "Dirty Grandpa" and STX Entertainment's "The Boy," with the two newcomers debuting at a respective $11.5M and $11.3M.
1 | 2 | 3 >>

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use